Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition
© 2018 John Wiley & Sons Ltd..
AIM: To test the cross-immunogenicity of anti-CT-P13 IBD patients' sera to CT-P13/infliximab originator and the comparative antigenicity evoked by CT-P13/infliximab originator sera.
METHODS: Sera of patients with IBD with measurable anti-CT-P13 antibodies were tested for their cross-reactivity to 5 batches of infliximab originator and CT-P13. Anti-drug antibody positive sera from treated patients were used to compare antigenic epitopes.
RESULTS: All 42 anti-CT-P13 and 37 anti-infliximab originator IBD sera were cross-reactive with infliximab originator and CT-P13 respectively. Concentration of anti-drug antibodies against infliximab originator or CT-P13 were strongly correlated both for IgG1 and IgG4 (P < 0.001). Anti-CT-P13 sera of patients with IBD (n = 32) exerted similar functional inhibition on CT-P13 or infliximab originator TNF binding capacity and showed reduced binding to CT-P13 in the presence of five different batches of CT-P13 and infliximab originator. Anti-CT-P13 and anti-infliximab originator IBD sera selectively enriched phage-peptides from the VH (CDR1 and CDR3) and VL domains (CDR2 and CDR3) of infliximab. Sera reactivity detected major infliximab epitopes in these regions of infliximab in 60%-79% of patients, and no significant differences were identified between CT-P13 and infliximab originator immunogenic sera. Minor epitopes were localised in framework regions of infliximab with reduced antibody reactivity shown, in 30%-50% of patients. Monoclonal antibodies derived from naïve individuals and ADA-positive IBD patients treated with CT-P13 provided comparable epitope specificity to five different batches of CT-P13 and infliximab originator.
CONCLUSIONS: These results strongly support a similar antigenic profile for infliximab originator and CT-P13, and point toward a safe switching between the two drugs in anti-drug antibody negative patients.
| Errataetall: |
CommentIn: Aliment Pharmacol Ther. 2018 Sep;48(5):574-575. - PMID 30156324 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 48(2018), 5 vom: 01. Sept., Seite 507-522 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goncalves, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 27.09.2019 Date Revised 09.04.2022 published: Print-Electronic CommentIn: Aliment Pharmacol Ther. 2018 Sep;48(5):574-575. - PMID 30156324 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.14808 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM285179896 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM285179896 | ||
| 003 | DE-627 | ||
| 005 | 20231225044848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.14808 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0950.xml |
| 035 | |a (DE-627)NLM285179896 | ||
| 035 | |a (NLM)29873091 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goncalves, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2019 | ||
| 500 | |a Date Revised 09.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Aliment Pharmacol Ther. 2018 Sep;48(5):574-575. - PMID 30156324 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 John Wiley & Sons Ltd. | ||
| 520 | |a AIM: To test the cross-immunogenicity of anti-CT-P13 IBD patients' sera to CT-P13/infliximab originator and the comparative antigenicity evoked by CT-P13/infliximab originator sera | ||
| 520 | |a METHODS: Sera of patients with IBD with measurable anti-CT-P13 antibodies were tested for their cross-reactivity to 5 batches of infliximab originator and CT-P13. Anti-drug antibody positive sera from treated patients were used to compare antigenic epitopes | ||
| 520 | |a RESULTS: All 42 anti-CT-P13 and 37 anti-infliximab originator IBD sera were cross-reactive with infliximab originator and CT-P13 respectively. Concentration of anti-drug antibodies against infliximab originator or CT-P13 were strongly correlated both for IgG1 and IgG4 (P < 0.001). Anti-CT-P13 sera of patients with IBD (n = 32) exerted similar functional inhibition on CT-P13 or infliximab originator TNF binding capacity and showed reduced binding to CT-P13 in the presence of five different batches of CT-P13 and infliximab originator. Anti-CT-P13 and anti-infliximab originator IBD sera selectively enriched phage-peptides from the VH (CDR1 and CDR3) and VL domains (CDR2 and CDR3) of infliximab. Sera reactivity detected major infliximab epitopes in these regions of infliximab in 60%-79% of patients, and no significant differences were identified between CT-P13 and infliximab originator immunogenic sera. Minor epitopes were localised in framework regions of infliximab with reduced antibody reactivity shown, in 30%-50% of patients. Monoclonal antibodies derived from naïve individuals and ADA-positive IBD patients treated with CT-P13 provided comparable epitope specificity to five different batches of CT-P13 and infliximab originator | ||
| 520 | |a CONCLUSIONS: These results strongly support a similar antigenic profile for infliximab originator and CT-P13, and point toward a safe switching between the two drugs in anti-drug antibody negative patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Biosimilar Pharmaceuticals |2 NLM | |
| 650 | 7 | |a CT-P13 |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Peptide Library |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 700 | 1 | |a Santos, M |e verfasserin |4 aut | |
| 700 | 1 | |a Acurcio, R |e verfasserin |4 aut | |
| 700 | 1 | |a Iria, I |e verfasserin |4 aut | |
| 700 | 1 | |a Gouveia, L |e verfasserin |4 aut | |
| 700 | 1 | |a Matos Brito, P |e verfasserin |4 aut | |
| 700 | 1 | |a Catarina Cunha-Santos, A |e verfasserin |4 aut | |
| 700 | 1 | |a Barbas, A |e verfasserin |4 aut | |
| 700 | 1 | |a Galvão, J |e verfasserin |4 aut | |
| 700 | 1 | |a Barbosa, I |e verfasserin |4 aut | |
| 700 | 1 | |a Aires da Silva, F |e verfasserin |4 aut | |
| 700 | 1 | |a Alcobia, A |e verfasserin |4 aut | |
| 700 | 1 | |a Cavaco, M |e verfasserin |4 aut | |
| 700 | 1 | |a Cardoso, M |e verfasserin |4 aut | |
| 700 | 1 | |a Delgado Alves, J |e verfasserin |4 aut | |
| 700 | 1 | |a Carey, J J |e verfasserin |4 aut | |
| 700 | 1 | |a Dörner, T |e verfasserin |4 aut | |
| 700 | 1 | |a Eurico Fonseca, J |e verfasserin |4 aut | |
| 700 | 1 | |a Palmela, C |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, J |e verfasserin |4 aut | |
| 700 | 1 | |a Lima Vieira, C |e verfasserin |4 aut | |
| 700 | 1 | |a Trabuco, D |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorino, G |e verfasserin |4 aut | |
| 700 | 1 | |a Strik, A |e verfasserin |4 aut | |
| 700 | 1 | |a Yavzori, M |e verfasserin |4 aut | |
| 700 | 1 | |a Rosa, I |e verfasserin |4 aut | |
| 700 | 1 | |a Correia, L |e verfasserin |4 aut | |
| 700 | 1 | |a Magro, F |e verfasserin |4 aut | |
| 700 | 1 | |a D'Haens, G |e verfasserin |4 aut | |
| 700 | 1 | |a Ben-Horin, S |e verfasserin |4 aut | |
| 700 | 1 | |a Lakatos, P L |e verfasserin |4 aut | |
| 700 | 1 | |a Danese, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 48(2018), 5 vom: 01. Sept., Seite 507-522 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2018 |g number:5 |g day:01 |g month:09 |g pages:507-522 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.14808 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2018 |e 5 |b 01 |c 09 |h 507-522 | ||